贝卡莱因的分子标和治疗潜力:一篇综述
Kavita Munjal1, Yash Goel2, Vinod Kumar Gauttam3
1Department of Pharmacognosy, Amity Institute of Pharmacy, Amity University, Noida, Uttar Pradesh - India.
Drug target insights
|June 14, 2024
概括
拜卡莱因是一种来自Scutellaria baicalensis等草药的黄类化合物,显示出作为抗氧化剂和抗炎剂的前景. 需要进一步的临床研究来确认其治疗用途的安全性和有效性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
- 药用化学 医学化学
背景情况:
- 由于其抗氧化和抗炎性质,黄素经常被用于药物发现.
- 拜卡莱因是一种关键的黄类化合物,已显示出广泛的潜在药理学活性.
研究的目的:
- 对贝卡莱因的药理作用和分子标进行详细的审查.
- 探索来自诸如Scutellaria baicalensis*和Oroxylum indicum*之类的植物的拜卡莱因的治疗潜力.
主要方法:
- 在体外和体内对贝卡莱因的研究的系统文献综述.
- 搜索了包括PubMed,ScienceDirect,Scopus和谷歌学者在内的数据库,截至2023年12月21日.
- 使用的关键词: *Scutellaria baicalensis*, *Oroxylum indicum*,神经保护性,心脏保护性,毒性研究和Baicalein.
主要成果:
- 拜卡莱因表现出抗癌,抗糖尿病,抗微生物,抗衰老,神经保护,心脏保护,呼吸,胃肠道,肝脏和脏的保护作用.
- 这些效应与贝卡莱因的分子受体结合能力有关.
- 与其他草药的协同作用增强了拜卡莱因的治疗潜力.
结论:
- 拜卡莱因显示出作为一种补充药物的潜力,为*S. baicalensis*和*O. indicum*提供了洞察力.
- 建议进行进一步的临床和机制研究,以验证baicalein的安全性和有效性.
- 拜卡莱因可能会被开发成更有效的基于证据的药物.
更多相关视频
10:21Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
Published on: February 23, 2024
2.5K
10:25Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology
Published on: November 22, 2024
252
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...